Glycan Therapeutics Corporation
Publicly observedRaleigh, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Raleigh | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Glycan Therapeutics Corporation | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KYG3DZSMH4R7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant21 Sept 2023Publicly observed
NIH SBIR/STTR award: Synthesis of the library of heparan sulfate hexasaccharide mimetics
USD 1,075,790.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant16 Aug 2023Publicly observed
NIH SBIR/STTR award: Development of anticoagulant sulfated glycans
USD 1,061,433.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant14 Sept 2021Publicly observed
NIH SBIR/STTR award: Development of heparan sulfate-based therapeutics to treat inflammatory diseases
USD 50,000.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2017Publicly observed
NIH SBIR/STTR award: Development of dekaparin to replace animal-sourced heparin
USD 991,212.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.